S&P 500   4,004.49 (+0.04%)
DOW   32,530.02 (-0.09%)
QQQ   311.62 (+0.41%)
AAPL   159.96 (+0.43%)
MSFT   276.82 (+1.11%)
META   203.75 (+0.79%)
GOOGL   104.93 (+0.01%)
AMZN   100.34 (-0.27%)
TSLA   197.93 (+0.18%)
NVDA   269.26 (+2.77%)
NIO   9.32 (+0.54%)
BABA   85.07 (+1.64%)
AMD   97.98 (+2.14%)
T   18.64 (+0.54%)
F   11.90 (+1.54%)
MU   58.88 (+0.43%)
CGC   1.97 (-0.25%)
GE   92.54 (+0.39%)
DIS   96.77 (+0.24%)
AMC   4.65 (+5.44%)
PFE   40.62 (-0.10%)
PYPL   75.88 (-1.09%)
NFLX   302.70 (-1.01%)
S&P 500   4,004.49 (+0.04%)
DOW   32,530.02 (-0.09%)
QQQ   311.62 (+0.41%)
AAPL   159.96 (+0.43%)
MSFT   276.82 (+1.11%)
META   203.75 (+0.79%)
GOOGL   104.93 (+0.01%)
AMZN   100.34 (-0.27%)
TSLA   197.93 (+0.18%)
NVDA   269.26 (+2.77%)
NIO   9.32 (+0.54%)
BABA   85.07 (+1.64%)
AMD   97.98 (+2.14%)
T   18.64 (+0.54%)
F   11.90 (+1.54%)
MU   58.88 (+0.43%)
CGC   1.97 (-0.25%)
GE   92.54 (+0.39%)
DIS   96.77 (+0.24%)
AMC   4.65 (+5.44%)
PFE   40.62 (-0.10%)
PYPL   75.88 (-1.09%)
NFLX   302.70 (-1.01%)
S&P 500   4,004.49 (+0.04%)
DOW   32,530.02 (-0.09%)
QQQ   311.62 (+0.41%)
AAPL   159.96 (+0.43%)
MSFT   276.82 (+1.11%)
META   203.75 (+0.79%)
GOOGL   104.93 (+0.01%)
AMZN   100.34 (-0.27%)
TSLA   197.93 (+0.18%)
NVDA   269.26 (+2.77%)
NIO   9.32 (+0.54%)
BABA   85.07 (+1.64%)
AMD   97.98 (+2.14%)
T   18.64 (+0.54%)
F   11.90 (+1.54%)
MU   58.88 (+0.43%)
CGC   1.97 (-0.25%)
GE   92.54 (+0.39%)
DIS   96.77 (+0.24%)
AMC   4.65 (+5.44%)
PFE   40.62 (-0.10%)
PYPL   75.88 (-1.09%)
NFLX   302.70 (-1.01%)
S&P 500   4,004.49 (+0.04%)
DOW   32,530.02 (-0.09%)
QQQ   311.62 (+0.41%)
AAPL   159.96 (+0.43%)
MSFT   276.82 (+1.11%)
META   203.75 (+0.79%)
GOOGL   104.93 (+0.01%)
AMZN   100.34 (-0.27%)
TSLA   197.93 (+0.18%)
NVDA   269.26 (+2.77%)
NIO   9.32 (+0.54%)
BABA   85.07 (+1.64%)
AMD   97.98 (+2.14%)
T   18.64 (+0.54%)
F   11.90 (+1.54%)
MU   58.88 (+0.43%)
CGC   1.97 (-0.25%)
GE   92.54 (+0.39%)
DIS   96.77 (+0.24%)
AMC   4.65 (+5.44%)
PFE   40.62 (-0.10%)
PYPL   75.88 (-1.09%)
NFLX   302.70 (-1.01%)
NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$74.18
-0.40 (-0.54%)
(As of 03/22/2023 10:41 AM ET)
Add
Compare
Today's Range
$73.74
$75.45
50-Day Range
$73.16
$84.27
52-Week Range
$47.67
$89.59
Volume
35,021 shs
Average Volume
199,633 shs
Market Capitalization
$1.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.25

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.6% Upside
$119.25 Price Target
Short Interest
Bearish
5.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.61mentions of Krystal Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$7.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.57) to ($2.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

167th out of 983 stocks

Biological Products, Except Diagnostic Industry

26th out of 163 stocks


KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

This Stock Has Room To Run
Analysts believe this stock's product demand could rise quickly in the next few years.
Guggenheim Reaffirms Their Buy Rating on Krystal Biotech (KRYS)
Expert Ratings for Krystal Biotech
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
Krystal Biotech (KRYS) was upgraded to a Buy Rating at Goldman Sachs
Krystal Biotech’s stock is down on delayed PDUFA date
BofA Securities: The most promising biotech stocks in 2023
12 Best Small-Cap Healthcare Stocks To Buy Now
2 Risky Stocks That Could Soar in 2023
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
2/27/2023
Today
3/22/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
119
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$119.25
High Stock Price Forecast
$133.00
Low Stock Price Forecast
$101.00
Forecasted Upside/Downside
+59.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-139,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$20.28 per share

Miscellaneous

Free Float
21,178,000
Market Cap
$1.92 billion
Optionable
Not Optionable
Beta
0.87

Social Links


Key Executives

  • Krish S. Krishnan
    Chairman, President & Chief Executive Officer
  • Suma M. KrishnanSuma M. Krishnan
    Director, President-Research & Development
  • George Chen
    Manager-Information Technology & CSV
  • Trevor Parry
    Senior Director-Scientific Affairs
  • David Glynn
    General Counsel & Head-Commercial & Compliance













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

4 brokerages have issued twelve-month price targets for Krystal Biotech's stock. Their KRYS share price forecasts range from $101.00 to $133.00. On average, they predict the company's share price to reach $119.25 in the next twelve months. This suggests a possible upside of 59.9% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 on January 1st, 2023. Since then, KRYS shares have decreased by 5.9% and is now trading at $74.58.
View the best growth stocks for 2023 here
.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,190,000 shares, an increase of 6.3% from the February 13th total of 1,120,000 shares. Based on an average trading volume of 189,800 shares, the short-interest ratio is presently 6.3 days. Currently, 5.7% of the shares of the stock are sold short.
View Krystal Biotech's Short Interest
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings data on Monday, February, 27th. The company reported ($1.25) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.01.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.48%), Lord Abbett & CO. LLC (4.96%), Frazier Life Sciences Management L.P. (3.88%), Credit Suisse AG (2.65%), Point72 Asset Management L.P. (2.16%) and First Light Asset Management LLC (1.84%). Insiders that own company stock include Dino A Rossi, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $74.58.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $1.92 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.51) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 119 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 3/22/2023 by MarketBeat.com Staff